Kyverna therapeutics appoints naji gehchan, md, mba, as chief medical and development officer

Dr. gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing kyverna's senior leadership team to execute company's next wave of growth emeryville, calif. , jan. 21, 2025 /prnewswire/ -- kyverna therapeutics, inc. (kyverna, nasdaq: kytx), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the appointment of naji gehchan, m.d.
KYTX Ratings Summary
KYTX Quant Ranking